The recently reported simultaneous reduction of inflammatory activity, e.g., as documented by simultaneous reduction of IL-6 levels and ischemic events by treatment with the anti-inflammatory agents canakinumab [37] and colchicine [38], further supports inflammatory activity as a major pathophysiological mechanism in CHD [39]. This evidence concerns the gene IL6 and coronary artery disorder.